Estrella Immunopharma, Inc. (ESLA)

NASDAQ: ESLA · Real-Time Price · USD
0.800
-0.015 (-1.80%)
At close: Oct 31, 2024, 4:00 PM
0.753
-0.047 (-5.91%)
After-hours: Oct 31, 2024, 4:42 PM EDT
-1.80%
Market Cap 28.95M
Revenue (ttm) n/a
Net Income (ttm) -7.31M
Shares Out 36.19M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,457
Open 0.815
Previous Close 0.815
Day's Range 0.630 - 0.880
52-Week Range 0.630 - 3.230
Beta 0.18
Analysts n/a
Price Target n/a
Earnings Date Nov 5, 2024

About ESLA

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country United States
Stock Exchange NASDAQ
Ticker Symbol ESLA
Full Company Profile

Financial Performance

Financial Statements

News

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEM...

4 weeks ago - Business Wire

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", “Estrella Immunopharma”, or the "Company"), a clinical stage biopharmaceutical company focused on de...

2 months ago - Business Wire

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as Trade...

1 year ago - PRNewsWire

Estrella Immunopharma Nears Completion Of SPAC Listing

Estrella Immunopharma is nearing completion of its New York listing using a SPAC backed by China's UP Fintech. The cancer therapy developer was only founded last year but thinks it can start generatin...

1 year ago - Seeking Alpha

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

NEW YORK , Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its...

1 year ago - PRNewsWire

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. ("TradeUP") (...

2 years ago - PRNewsWire